ROBIN MILLER: Open Payments
NPI 1801453014 · ROSEVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,189 in 55 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $521 · 2025 $1,189
Food & beverage: $1,189
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $379 |
| Madrigal Pharmaceuticals | 6 | $262 |
| Ardelyx, Inc. | 12 | $192 |
| Janssen Biotech, Inc. | 4 | $88 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $45 |
| Janssen Pharmaceuticals, Inc | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Braintree Laboratories, Inc. | 1 | $29 |
| ABBVIE INC. | 2 | $28 |
Products named: ENTYVIO, REZDIFFRA, IBSRELA, TREMFYA, EOHILIA, VOQUEZNA, XIFAXAN, DUPIXENT.
Industry payments across CA — which companies pay providers there.
